AtriCure (ATRC) Tops Q3 EPS by 2c, provides guidance

AtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $115.9 million versus the consensus estimate of $112.23 million.
FY 2024 Guidance:
EPS: ($0.74) - ($0.80), versus the guidance of ($0.77)

Revenue: $459 - $462 million, versus the guidance of $458.1 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Hinge Health signs $86M office lease in San Francisco
• Kimbell Royalty closes $221.2M mineral rights acquisition